HCB-101

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameHCB-101
Drug Alias NameSIRPα-IgG4 Fc融合蛋白an engineered immunoglobulin variable (IgV) domain of human SIRPalpha fused to human IgG4 Fc proteinHCB-101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursStomach NeoplasmsColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHanchorBio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInstitute of Tsinghua University, HebeiGuangzhou Hanke Biological Co LtdHanchorBio Inc +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach NeoplasmsColorectal Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A